Through its Access Support program, Bristol Myers Squibb (BMS) offers a variety of options to help provide eligible patients access to its oncology medications and reimbursement support services. The program offers benefits reviews, prior authorization assistance, and appeal process support, as well as an easy-to-initiate copay assistance process and information on financial support. The support offered varies based on the patient’s prescribed medication and insurance status. See the Table for a list of oncology and oncology supportive drugs, drug indications, and program information.
BMS Access Support
BMS Oncology Co-Pay Assistance Program
Access to certain BMS oncology products is supported through the BMS Oncology Co-Pay Assistance Program. This program is designed for commercially insured patients who need financial assistance with out-of-pocket deductibles, copays, or coinsurance.
Enrolled patients pay the first $25 of the copay for each dose of a BMS medication covered by this program. BMS will cover the remaining amount up to a maximum of $25,000 per year, per patient, per product. Restrictions apply. Final determination of program eligibility is based upon review of a completed application.
Click here for access to program information pertaining to the drug you have prescribed for your patient. More information can also be obtained by calling BMS Access Support at 800-861-0048.
Patients with government insurance, such as Medicare, Medicaid, or TRICARE, are not eligible for copay assistance programs sponsored by BMS. See information below regarding options for these patients, including the BMS Patient Assistance Foundation.
Enrollment forms for the BMS Oncology Co-Pay Assistance Program are available online. Print the enrollment form, which must be completed and signed by the patient and the provider and faxed to BMS. For patients prescribed Opdivo, Yervoy, Empliciti, or Sprycel, fax the completed form to 888-776-2370; for Revlimid, Pomalyst, Thalomid, Inrebic, Idhifa, Onureg, or Abraxane, fax to 800-822-2496. The BMS Access Support program will determine the patient’s eligibility, including verification of insurance coverage and benefits amount.
BMS Patient Assistance Foundation
For patients who have government insurance, are underinsured, or have no prescription drug insurance, BMS Access Support can make a referral to independent charitable foundations. Each foundation has its own eligibility criteria and evaluation process. BMS cannot guarantee that a patient will receive assistance.
The BMS Patient Assistance Foundation (BMSPAF) may provide medicine, free of charge, to eligible, uninsured patients who have an established financial hardship. BMSPAF may be able to provide assistance to patients who:
Live in the United States, Puerto Rico, or the US Virgin Islands
Are being treated by a US licensed prescriber
Are being treated with the medicine as an outpatient
Do not have insurance coverage for a listed medicine
Were prescribed a BMS medicine for cancer (even if their annual household income is higher than $38,640 for a single person or $52,260 for a family of 2).
These are just some of the eligibility requirements, and other eligibility criteria may apply. For more information, call BMS at 800-736-0003 or visit BMSPAF.org.
The application for the BMSPAF can be downloaded from BMSPAF.org. Both the patient and the healthcare provider must complete appropriate sections, sign, and date the application. Proof of income must be submitted with the application. Fax documents to BMSPAF at 888-776-2370. Enrollment is valid for 1 year; re-enrollment every year is required to continue in the program.
TABLE Bristol Myers Squibb Oncology Drugs
Drugs
Indications
Patient support programs
Drug
Abraxane (paclitaxel protein-bound particles) for injectable suspension
Indications
Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy; locally advanced or metastatic NSCLC, in combination with carboplatin; metastatic pancreatic cancer, in combination with gemcitabine
Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion
Indications
Treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
Continued treatment of adults with acute myeloid leukemia who achieved first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and are not able to complete intensive curative therapy
Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received 1 to 3 prior therapies; treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adult patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor
Opdivo (nivolumab) Indications
Unresectable or metastatic melanoma with BRAF V600 wild-type; adjuvant treatment of melanoma with lymph node involvement or metastatic melanoma in patients who have undergone complete resection; first-line treatment, in combination with ipilimumab, of metastatic NSCLC and PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; first-line treatment, in combination with platinum-doublet chemotherapy and ipilimumab, of metastatic or recurrent NSCLC and no EGFR or ALK mutations; first-line treatment of NSCLC progressing during or after platinum-based chemotherapy, or, in patients with EGFR or ALK mutations, during an FDA-approved therapy for these aberrations; first-line treatment, in combination with ipilimumab, of adults with unresectable malignant pleural mesothelioma; advanced renal-cell carcinoma, in patients who have received previous antiangiogenic therapy; intermediate- or poor-risk, untreated advanced renal-cell carcinoma, in combination with ipilimumab; classical Hodgkin lymphoma that relapsed or progressed after autologous HSCT; recurrent or metastatic squamous-cell head and neck carcinoma progressing during or after platinum-based therapy; locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer that progressed after a regimen of fluoropyrimidine, oxaliplatin, and irinotecan; treatment of patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with ipilimumab; unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine- and platinum-based chemotherapy; treatment, in combination with ipilimumab, of hepatocellular carcinoma after sorafenib therapy
Pomalyst (pomalidomide) Indications
Multiple myeloma, in combination with dexamethasone, after at least 2 therapies, including lenalidomide and a proteasome inhibitor, in patients whose disease progressed during or within 60 days of completing the last therapy; treatment of patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative
Revlimid (lenalidomide) capsules Indications
Multiple myeloma, in combination with dexamethasone or as maintenance after autologous hematopoietic stem-cell transplant; transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q; mantle-cell lymphoma in patients whose disease relapsed or progressed after 2 therapies, including bortezomib; previously treated follicular lymphoma, in combination with rituximab-containing therapy; previously treated marginal-zone lymphoma, in combination with rituximab-containing therapy
Yervoy (ipilimumab) Indications
Treatment of unresectable or metastatic melanoma in patients ≥12 years; treatment of unresectable or metastatic melanoma in adult patients in combination with nivolumab; adjuvant treatment of patients with cutaneous melanoma and involvement of regional lymph nodes >1 mm after complete resection, including total lymphadenectomy; first-line treatment of intermediate- or poor-risk advanced renal-cell carcinoma, in combination with nivolumab; treatment of patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab; treatment of hepatocellular carcinoma after sorafenib therapy, in combination with nivolumab; first-line treatment of metastatic NSCLC expressing PD-L1 (≥1%), as determined by an FDA-approved test, and no EGFR or ALK genomic tumor aberrations, in combination with nivolumab; first-line treatment, in combination with 2 cycles of platinum-doublet chemotherapy and nivolumab, of metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations; first-line treatment of adults with unresectable malignant pleural mesothelioma, in combination with nivolumab
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
